← Back to headlines
UBS Initiates Coverage on Jasper Therapeutics (JSPR) at Neutral
UBS has begun its coverage of Jasper Therapeutics (JSPR) with a 'Neutral' rating, despite acknowledging progress in the company's drug Briquilimab.
29 Mar, 20:50 — 29 Mar, 20:50
Sources
Showing 1 of 1 sources
Related Stories
Study Reveals Elderly More Vulnerable to Extreme Heat Than Previously Thought
3h ago
Nollywood Actor Ogogo Hassan's Daughters Seek Help for Father's Stage 4 Cancer
6h ago
Cancer Survivor Erin Races Against Time for Chance of Motherhood
6h ago
West Nile Fever Spreads in North Macedonia and Serbia, Causing Deaths
7h ago